aminolevulinic acid Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
166 106-60-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ameluz
  • aminolevulinic acid
  • 5-amino-4-oxopentanoic acid
  • aladerm
  • alasens
  • 5-aminolevulinic acid
  • 5-aminolevulinic acid hydrochloride
  • Gliolan
  • aminolevulinic acid hydrochloride
  • 5-aminolevulinic acid HCl
  • aminolevulinic acid HCl
A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
  • Molecular weight: 131.13
  • Formula: C5H9NO3
  • CLOGP: -3.41
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 80.39
  • ALOGS: 0.12
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.88 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.88 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.83 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 3, 1999 FDA DUSA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site erythema 110.76 108.37 20 266 4884 46680892

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC L01XD04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Sensitizers used in photodynamic/radiation therapy
FDA CS M0017335 Porphyrinogens
MeSH PA D003879 Dermatologic Agents
MeSH PA D017319 Photosensitizing Agents
MeSH PA D011838 Radiation-Sensitizing Agents
FDA EPC N0000175846 Porphyrin Precursor
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:47868 photosensitising agent
CHEBI has role CHEBI:50177 dermatological agent
CHEBI has role CHEBI:50266 prodrugs
CHEBI has role CHEBI:75771 mus musculus metabolite
CHEBI has role CHEBI:75772 baker's yeast metabolite
CHEBI has role CHEBI:76924 plant metabolites
CHEBI has role CHEBI:76971 e.coli metabolites
CHEBI has role CHEBI:77746 h. sapiens metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Fluorescent stain indication 35352008
Actinic keratosis indication 201101007 DOID:8866
Non-Hyperkeratotic Actinic Keratoses indication
Photosensitivity contraindication 90128006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.82 acidic
pKa2 9.59 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
20% LEVULAN DUSA N020965 Dec. 3, 1999 RX SOLUTION TOPICAL March 9, 2021 TREATMENT OF MINIMALLY TO MODERATELY THICK ACTINIC KERATOSIS OF THE UPPER EXTREMITIES IN CONJUNCTION WITH A BLUE LIGHT PHOTODYNULLMIC THERAPY ILLUMINULLTOR
1.5GM/VIAL GLEOLAN NXDC N208630 June 6, 2017 RX FOR SOLUTION ORAL June 6, 2024 OPTICAL IMAGING AGENT INDICATED IN PATIENTS WITH GLIOMA (SUSPECTED WORLD HEALTH ORGANIZATION GRADES III OR IV ON PREOPERATIVE IMAGING) AS AN ADJUNCT FOR THE VISUALIZATION OF MALIGNULLNT TISSUE DURING SURGERY

Bioactivity Summary:

None

External reference:

IDSource
88755TAZ87 UNII
4025779 VUID
N0000176068 NUI
D02908 KEGG_DRUG
5451-09-2 SECONDARY_CAS_RN
C0002563 UMLSCUI
CHEBI:17549 CHEBI
FVT PDB_CHEM_ID
CHEMBL1200582 ChEMBL_ID
CHEMBL601 ChEMBL_ID
137 PUBCHEM_CID
DB00855 DRUGBANK_ID
D000622 MESH_DESCRIPTOR_UI
4784 IUPHAR_LIGAND_ID
1806646 RXNORM
228491 MMSL
30525 MMSL
8581 MMSL
d07530 MMSL
009074 NDDF
259496005 SNOMEDCT_US
409398000 SNOMEDCT_US
784354008 SNOMEDCT_US
4025779 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
AMELUZ HUMAN PRESCRIPTION DRUG LABEL 1 70621-101 GEL 100 mg TOPICAL NDA 26 sections
GLEOLAN HUMAN PRESCRIPTION DRUG LABEL 1 71469-231 POWDER, FOR SOLUTION 1500 mg ORAL NDA 26 sections